Novo Nordisk

Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence
Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence
Fierce Pharma
diabetes
patients
Novo Nordisk
drug discounts
outcomes-based pricing
Flag link:
Novo charts course for sickle cell amid headwinds in hemophilia
Novo charts course for sickle cell amid headwinds in hemophilia
Biopharma Dive
Novo Nordisk
sickle cell disease
hemophilia
EPI01
EpiDestiny
Flag link:
FDA approves label update to Novo Nordisk’s Tresiba diabetes drug
FDA approves label update to Novo Nordisk’s Tresiba diabetes drug
Drug Delivery Business News
FDA
Novo Nordisk
diabetes
Tresiba
labeling
insulin degludec
Flag link:
Pharma's social media strategies are growing up—and working better, too, report finds
Pharma's social media strategies are growing up—and working better, too, report finds
Fierce Pharma
social media
Novo Nordisk
JNJ
Novartis
Boehringer Ingelheim
Flag link:
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Drug Delivery Business News
Japan
Novo Nordisk
diabetes
type 2 diabetes
Ozempic
Flag link:
Drugmaker Novo Nordisk looks to former oil boss to energize M&A
Drugmaker Novo Nordisk looks to former oil boss to energize M&A
Reuters
Novo Nordisk
M&A
Helge Lund
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Fierce Pharma
Novo Nordisk
obesity
semaglutide
Flag link:
GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk
GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk
Market Realist
Novo Nordisk
GLP-1 agonist
diabetes
Victoza
Flag link:
[video]Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices
[video]Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices
Bloomberg
Novo Nordisk
Pharma CEOs
competition
drug pricing
Lars Fruergaard Jorgensen
Flag link:
Novo Nordisk secures Ozempic formulary coverage from Express Scripts
Novo Nordisk secures Ozempic formulary coverage from Express Scripts
Fierce Pharma
Novo Nordisk
Ozempic
Express Scripts
Flag link:
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Fierce Pharma
migraines
NASH
Amgen
Eli Lilly
Teva Pharmaceutical
Allergan
Gilead Sciences
Novo Nordisk
Intercept Pharma
PBMs
Flag link:
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
Endpoints
Novo Nordisk
Eli Lilly
diabetes
clinical trials
semaglutide
Trulicity
Flag link:
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Fierce Pharma
Novo Nordisk
semaglutide
Eli Lilly
Ozempic
Trulicity
Flag link:
Novo Nordisk’s once-weekly Type II diabetes med approved in Europe
Novo Nordisk’s once-weekly Type II diabetes med approved in Europe
Drug Delivery Business News
Novo Nordisk
diabetes
type 2 diabetes
Europe
Ozempic
Flag link:
Novo Nordisk's Dichotomy Abounds
Novo Nordisk's Dichotomy Abounds
Motley Fool
Novo Nordisk
diabetes
earnings
Flag link:
Novo Nordisk launches two new diabetes drugs in U.S.
Novo Nordisk launches two new diabetes drugs in U.S.
Drug Delivery Business News
Novo Nordisk
diabetes
Ozempic
Fiasp
Flag link:
Shares in Novo Nordisk sink after Q4 earnings, sales disappoint
Shares in Novo Nordisk sink after Q4 earnings, sales disappoint
Drug Delivery Business News
Novo Nordisk
earnings
Flag link:
Sanofi beats Novo to buy Ablynx for 3.9 billion euros in biotech M&A boom
Sanofi beats Novo to buy Ablynx for 3.9 billion euros in biotech M&A boom
Yahoo/Reuters
Sanofi
Novo Nordisk
M&A
biotech
Ablynx
Flag link:
Novo Nordisk’s once-weekly diabetes injection cleared in Canada
Novo Nordisk’s once-weekly diabetes injection cleared in Canada
Drug Delivery Business News
Novo Nordisk
diabetes
Canada
Ozempic
Flag link:

Pages